ClinicalTrials.gg
Not yet recruitingNCT07795775Updated Sep 2, 2026

Health Nanotechnology Education for Nursing Interns

An interventional study of Health Nanotechnology Educational Program in Nursing Education, sponsored by Mona Gabr. Not yet recruiting. Open to participants aged 20 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Mona Gabr · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
356
Allocation
Not applicable
Ages
20 Years to 25 Years
Sex
All
01

Study summary

This quasi-experimental study evaluates the effect of a health nanotechnology educational program on nursing interns' knowledge and self-perceived innovation readiness. Approximately 356 nursing interns at the Faculty of Nursing, Mansoura University, will complete a pretest assessment before participating in an 8-week educational program covering nanotechnology fundamentals, applications in healthcare and nursing, and related innovation topics. A posttest will be administered two months after program completion to assess changes in knowledge and innovation readiness.

Read the detailed description

The study follows a single-group pretest-posttest design conducted in four phases: Assessment, Planning, Implementation, and Evaluation. In the Assessment phase, baseline knowledge and innovation readiness are measured using two validated tools. In the Planning phase, an educational program is developed based on the pretest results and a review of relevant literature. In the Implementation phase, the program is delivered face-to-face over 8 weeks (24 sessions, 2 hours each, totaling 48 contact hours) using interactive lectures, case-based discussions, and other participatory teaching methods across six content areas related to health nanotechnology. In the Evaluation phase, a posttest is administered two months after program completion to assess changes in knowledge and innovation readiness compared to baseline.

02

Conditions studied

  • Nursing Education

Browse trials for

Keywords

  • Nanotechnology
  • Nursing Interns
  • Health Education
  • Innovation Readiness
03

In context

Health Education

483 studies on the registry are indexed under Health Education; 112 are open to participants now.

This study's planned enrollment of 356 is above the median of 132 across 452 interventional studies indexed under Health Education.

Browse Health Education studies →

Lead sponsor

This is the only study on the registry with Mona Gabr as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Officially enrolled nursing interns for the academic year 2025/2026
  • Willing to provide voluntary to participate
  • Willing to attend all program sessions
  • Available for both pretest and posttest assessments

Exclusion criteria

Exclusion Criteria:

  • Refusal to provide consent
  • Previous participation in a similar educational program
  • Participation in the pilot study
  • Frequent absence or failure to complete the assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
356 participants (estimated)

Study arms

  • Experimental
    Nanotechnology Education Program

    Nursing interns receiving the 8-week health nanotechnology educational program (24 sessions, 2 hours each) covering nanotechnology fundamentals and applications in healthcare and nursing.

    Behavioral: Health Nanotechnology Educational Program

Interventions

  • BehavioralHealth Nanotechnology Educational Program

    An 8-week face-to-face educational program (24 sessions, 2 hours each, 48 total contact hours) covering nanotechnology fundamentals, applications in healthcare and nursing, and related innovation topics, delivered through interactive lectures, case-based discussions, and other participatory teaching methods.

06

What researchers measure

Primary outcomes

  1. Change in Knowledge of Health Nanotechnology

    Change in nursing interns' knowledge scores related to health nanotechnology, measured using the Health Nanotechnology Knowledge Assessment Tool (NKAT), a 50-item tool with scores ranging from 0 to 50, where higher scores indicate better knowledge.

    Time frame: Baseline (pre-intervention) and two months after completion of the 8-week educational program

Secondary outcomes

  1. Change in Innovation Readiness

    Change in nursing interns' innovation readiness scores, measured using the Innovation Readiness Inventory, a 13-item, 5-point Likert scale with scores ranging from 13 to 65, where higher scores indicate more positive perception of innovation readiness.

    Time frame: Baseline (pre-intervention) and two months after completion of the 8-week educational program

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — No plan currently exists to share individual participant data beyond what is reported in publications resulting from this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 292 non-industry interventional studies with no phase under Health Education, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 4 months is below that.

Counting every sponsor, half of 293 studies reached it within 11 months; a quarter within 3 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartEst.
Sep 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07795775
Lead sponsor
Mona Gabr
Responsible party
Mona Gabr (Lecturer, Delta University for Science and Technology) — Sponsor-investigator
First posted
Aug 31, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Mona Ahmed Gabr, PHD
Contact
mona.gabr@deltauniv.edu.eg
00201097898593 ext. 002 ‭015681581

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion